Tag: dova pharmaceuticals

July 19, 2019

Dova Pharmaceuticals Announces DOPTELET Now Commercially Available in US

Dova Pharmaceuticals (NASDAQ:DOVA) has announced DOPTELET is now commercially available to treat thrombocytopenia in adults with chronic immune thrombocytopenia. As...
June 30, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Dova Up 52 Percent

INN looks at the five top NASDAQ biotech and pharma stocks last week and what moved their share prices during...
June 25, 2019

Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET®

Dova Pharmaceuticals (NASDAQ:DOVA) has announced that the European Commission (EC) has authorized DOPTELET for treating severe thombocytopenia in adult patients...
December 30, 2018

5 Top Weekly NASDAQ Biotech Stocks: Dova Up 41 Percent

Dova Pharmaceuticals, Sesen Bio, Adaptimmune Therapeutics, Mustang Bio and Equillium were last week's top gainers.
September 27, 2018

Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET (Avatrombopag)

Dova Pharmaceuticals (NASDAQ:DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is...